edatrexate has been researched along with Cancer of Prostate in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Begg, C; Cohen, L; Kelly, WK; Liebertz, C; Scher, HI; Schultz, PK | 1 |
| Kris, MG; Miller, VA; Scher, HI; Sirotnak, FM; Zakowski, MF | 1 |
1 trial(s) available for edatrexate and Cancer of Prostate
| Article | Year |
|---|---|
Post-therapy change in prostate-specific antigen levels as a clinical trial endpoint in hormone-refractory prostatic cancer: a trial with 10-ethyl-deaza-aminopterin.
Topics: Aged; Aminopterin; Antineoplastic Agents; Follow-Up Studies; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Treatment Outcome | 1994 |
1 other study(ies) available for edatrexate and Cancer of Prostate
| Article | Year |
|---|---|
Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase.
Topics: Aminopterin; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Carboplatin; Cell Division; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; ErbB Receptors; Female; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Male; Maximum Tolerated Dose; Mice; Mice, Nude; Neoplasm Transplantation; Paclitaxel; Prostatic Neoplasms; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Taxoids; Time Factors; Tumor Cells, Cultured; Vinblastine; Vinorelbine; Vulvar Neoplasms | 2000 |